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The best treatment for patients with end-stage renal disease is kidney transplantation.
Although graft survival rates have improved in the last decades, patients still may lose
their grafts partly due to the detrimental effects of donor-specific antibodies (DSA) against
human leukocyte antigens (HLA) and to a lesser extent also by antibodies directed against
non-HLA antigens expressed on the donor endothelium. Assays to detect anti-HLA
antibodies are already in use for many years and have been proven useful for transplant
risk stratification. Currently, there is a need for assays to additionally detect multiple
non-HLA antibodies simultaneously in order to study their clinical relevance in solid organ
transplantation. This study describes the development, technical details and validation
of a high-throughput multiplex assay for the detection of antibodies against 14 non-HLA
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antigens coupled directly to MagPlex microspheres or indirectly via a HaloTag. The
non-HLA antigens have been selected based on a literature search in patients with kidney
disease or following transplantation. Due to the flexibility of the assay, this approach can
be used to include alternative antigens and can also be used for screening of other organ
transplant recipients, such as heart and lung.
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INTRODUCTION
Kidney transplantation is the preferred treatment for most
patients with end-stage renal disease. Pretransplant donor-
specific anti-human leukocyte antigen (HLA) antibodies (DSA)
have been shown to be a major risk factor in kidney graft loss
(1–3). In recent years non-HLA antibodies are increasingly being
recognized as a cause for antibody-mediated graft dysfunction
leading to graft loss, due to reports of antibody-mediated
rejection or C4d deposition in the absence of circulating DSA
(4–6). A landmark study (7) in 2005 indicated a role for non-
HLA immunity by showing a relation between graft loss in
HLA-identical sibling kidney transplants and percentage panel-
reactive antibodies (PRA) against HLA antigens. As graft loss
could not be attributed to DSA, PRA served as an indicator
of increased immunity against the graft, including non-HLA
antigens (7). In the past years, several reports have been
published describing AMR in the absence of circulating DSA
(8–17). These reports have raised interest in the identification
of immunogenic non-HLA molecules and a number of target
antigens were identified. At present, there is a need for the
development of coherent screening assays for the detection
of multiple non-HLA antibodies simultaneously in order to
study their clinical relevance in solid organ transplantation
(18).
Based on a literature search we have selected fourteen
non-HLA targets deemed relevant for kidney transplantation
(see Table 1 for a detailed description). Antibodies against
angiotensin-II type I receptor (AT1R) and endothelin type A
receptor (ETAR) expressed on the endothelium have already
been associated with kidney graft loss using a commercially
available ELISA (23, 25). The other twelve antibodies, found
in patients with kidney disease or after kidney transplant,
have not yet been associated with graft loss. In this study, we
describe the development, technical details, and validation of
a multiplex assay on a Luminex platform that can be used to
detect non-HLA antibodies in kidney transplant recipients. In
the PROCARE study (2) the clinical relevance of these non-HLA
antibodies will be measured in 4770 sera collected prior to kidney
Abbreviations: AMR, antibody-mediated rejection; APMAP, Adipocyte plasma
membrane-associated protein; ARHGDIB, Rho GDP-dissociation inhibitor 2;
ARHGEF6, Rho guanine nucleotide exchange factor 6; AT1R, Angiotensin
type I receptor; BPIFB1, BPI fold-containing family B member 1; DSA,
donor-specific anti-HLA antibodies; ETAR, Endothelin type A receptor; HLA,
human leukocyte antigen; IIFT, Indirect immunofluorescence test; N-GlcNAc,
N-Acetylglucosamine; PECR, Peroxisomal trans-2-enoyl-CoA reductase; PLA2R,
Phospholipase A2 receptor; PRA, Panel reactive antibodies; PRKCZ, Protein kinase
C zeta type; Tubb4B, Tubulin beta-4B.
transplantation, and the results will be reported separately. Using
this high-throughput assay, the non-HLA antibody status can be
determined in large cohorts and potentially be used in pre- and
post-transplant risk stratification.
MATERIALS AND METHODS
In-house Protein Production
For the production of the HaloTag-proteins, we generated a
universal vector containing the HaloTag R© open reading frame
[from the HaloTag R© CMVd1 Flexi R© Vector (Promega, Madison,
Wisconsin)] cloned in a pcDNA3.1 derived plasmid (Thermo
Fisher Scientific, Waltham, Massachusetts) with multiple cloning
site altered and added woodchuck posttranscriptional regulatory
element (WPRE) before the poly A tail in order to stabilize
the mRNA and enhance protein production (30). For PLA2R
without a HaloTag we used the pcDNA3.1-WPRE vector only.
We ordered the different inserts each starting with a BglII
restriction site, then a Kozak sequence and a standard signal
peptide, the codon optimized DNA sequence coding for the
protein of interest, followed by 6-Histidines for purification
purposes and ending with an XhoI restriction site from the
Invitrogen GeneArt Gene synthesis (Thermo Fisher Scientific)
(Figure 3). Using the BglII and XhoI restriction sites we
transferred the synthesized inserts from the suppliers vector
to our HaloTag expression vector (Figure 3). The amino acid
sequence used for the in-house produced proteins are provided
in Supplementary Table S1. For all constructs the complete open
reading frames were sequence verified by Sanger sequencing.
Subsequently, 1 x 108 HEK293-F cells were co-transfected with
a 100 µg DNA mix (containing per non-HLA an optimized
ratio of the pAdVAntageTM vector (Promega) and the vector
containing the sequence of the protein of interest) and 130
µg 293-Fectin in FreeStyle
TM
293 Expression Medium (both
Thermo Fisher Scientific). As the universal vector contained
a signal peptide, the proteins were secreted into the culture
supernatant, which was harvested at day 4. An AKTA start
protein purification system (GE Lifesciences, Chicago, Illinois)
fitted with a HisTrapTM HP column (GE Lifesciences) was used
to purify proteins from the cell supernatants. The fractions
containing the protein of interest were pooled. To remove
imidazole and other contaminants smaller than 10 kDa, the
pooled fractions were dialyzed to PBS in a Slide-A-Lyzer
TM
Dialysis Cassette 10 kDa (Thermo Fisher Scientific). The proteins
were detected by Western blot using various antibodies. See
Supplementary Table S2 for a list of all antibodies used in the
Western blot and their dilutions.
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TABLE 1 | Fourteen non-HLA proteins selected based on a literature search in patients with kidney disease or after kidney transplant.
Protein Other name UniProtKB Localization Expression References Patient population
Agrin O00468 Secreted,
extracellular matrix
Wide expression including
glomerular basement
membrane
(19) Patients with transplant
glomerulopathy
APMAP (Adipocyte plasma
membrane-associated protein)
C20orf3 Q9HDC9 Single pass
membrane protein
Ubiquitously expressed (20) Patients awaiting kidney
retransplant
ARHGDIB (Rho
GDP-dissociation inhibitor 2)
RhoGDI2 P52566 Intracellular:
cytoplasm
Wide expression including
renal pelvis and glomerulus
(21) Chronic hemodialysis patients
ARHGEF6 (Rho guanine
nucleotide exchange factor 6)
Q15052 Intracellular:
cytosol
Ubiquitously expressed (22) Pediatric kidney transplant
recipients
AT1R (Angiotensin type I
receptor)
P30556 Transmembrane
protein
Adipose and soft tissues (5, 23) Kidney transplant recipients
Endorepellin (C-terminal
fragment of perlecan)
P98160 Secreted,
extracellular matrix
Ubiquitously expressed (24) Kidney transplant recipients with
acute vascular rejection
ETAR (Endothelin type A
receptor)
EDNRA P25101 Transmembrane
protein
Ubiquitously expressed (25)) Kidney transplant recipients
Lamin B1 P20700 Intracellular:
Nuclear
membrane
Ubiquitously expressed (21) Chronic hemodialysis patients
LPLUNC1 (BPI fold-containing
family B member 1)
BPIFB1/
C20orf114
Q8TDL5 Secreted,
extracellular matrix
Respiratory epithelia,
stomach, small intestine and
salivary gland
(20) Patients awaiting kidney
retransplant
PECR (Peroxisomal
trans-2-enoyl-CoA reductase)
Q9BY49 Intracellular:
cytoplasm,
peroxisome
Ubiquitously expressed (26) Patients with transplant
glomerulopathy
PLA2R (Phospholipase A2
receptor)
Q13018 Membrane,
secreted
Renal glomeruli (27) Patients with membranous
nephropathy
PRKCZ (Protein kinase C zeta
type)
Q05513 Intracellular:
Cytoplasm
Ubiquitously expressed (28) Pediatric kidney transplant
recipients
Tubb4B (Tubulin beta-4B) P68371 Intracellular:
cytoplasm
Ubiquitously expressed (21) Chronic hemodialysis patients
Vimentin P08670 Intracellular:
cytoplasm
Ubiquitously expressed (21, 29) Chronic hemodialysis patients
and renal transplant recipients
with IFTA (interstitial fibrosis and
tubular atrophy)
Treatment With PNGase F
All purchased and in-house produced proteins with an
N-Acetylglucosamine (N-GlcNAc) according to UniProt
(Table 2) were treated with PNGase F (New England Biolabs)
according to manufacturer’s protocol. The PNGase F treated and
untreated proteins were detected by Western blot using various
antibodies (Supplementary Table S2).
Direct Coupling of Proteins to
Microspheres
First, using a Vivaspin R© 500 (Sartorius, Göttingen, Germany)
with pore size 10 kDa, 10 of the 15 purchased proteins which
were dissolved in glycerol or Tris-HCl were transferred to PBS.
Covalent coupling of the sixteen (proteins Table 2 upper part)
different carboxylated MagPlex R© Microspheres (Luminex Corp,
Austin, Texas) each with different emitting fluorescence pattern
was performed by following the procedures recommended by
Luminex (31). In short, 6.25× 106 microspheres (500µl of stock)
suspension was resuspended in microtiter tubes containing
0.1M sodium phosphate butter (pH 6.1) to a final volume of
200 µl. Fresh solutions of N-hydroxy-sulfosuccinimide (Sulfo-
NHS) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
hydrochloride (Pierce), both at 50 mg/ml, were prepared in
phosphate buffer, and 25 µl of each solution was sequentially
added to stabilize the reaction and activate the microspheres.
This suspension was incubated for 5min at room temperature
and then resuspended in 625 µl protein solution (1.5 µg protein
per 1× 106 microspheres). The mixture was incubated overnight
in the dark with continuous shaking. The microspheres were
then incubated with 625 µl PBS-0.05% Tween-20 for 4 h. After
aspiration, the microspheres were blocked with PBS-0.1% BSA-
0.1% sodium azide to a final concentration of 2,500 beads/µl. The
microspheres were counted on Beckman Coulter Counter and
stored in the dark at 4◦C. Coupling efficiency was tested using
anti-protein antibodies (Figure 1 and Supplementary Table S2).
Coupling of HaloTag Proteins to
Microspheres
First, microspheres were coupled with HaloTag Amine (O4)
Ligand (Promega). 6.25 × 106 microspheres were suspended in
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TABLE 2 | Overview of all purchased and in-house produced proteins.
Coupling Protein Source Company Size
including
Tags (kDa)
N-GlcNAc Glycosylation
confirmed by
PNGase F treatment
Direct IgG Human serum Sigma Aldrich 150 – –
Agrin CHO cell line R&D systems 100 No –
APMAP Wheat Germ (in vitro) Abnova 73 Yes No
ARHGDIB Wheat Germ (in vitro) Abnova 48 No –
ARHGEF6 Wheat Germ (in vitro) Abnova 114 No –
AT1R Wheat Germ (in vitro) with
proprietary liposome technology
Abnova 41 Yes No
Endorepellin Mouse myeloma cell line R&D systems 90 Yes Yes
ETAR Wheat Germ (in vitro) Abnova 75 Yes No
LMNB1 Wheat Germ (in vitro) Abnova 93 No –
LPLUNC1 HEK293 Cells Sino Biological Inc. 53 Yes Yes
PECR E coli Abcam 35 No –
PLA2R HEK293 Cells in-house production 160 Yes Yes
PRKCZ Wheat Germ (in vitro) Abnova 94 No –
Transferrin Serum of non-immunized
animals
Jackson ImmunoResearch 80 No –
TUBB4B Wheat Germ (in vitro) Abnova 75 No –
Vimentin E coli R&D systems 55 No –
HaloTag Agrin_HaloTag HEK293 cells in-house production with
HaloTag
138 No –
APMAP_HaloTag HEK293 cells in-house production with
HaloTag
85 Yes Yes
ARHGDIB_HaloTag HEK293 cells in-house production with
HaloTag
59 No –
ARHGEF6_HaloTag HEK293 cells in-house production with
HaloTag
126 No –
AT1R_HaloTag NA NA – – –
Endorepellin_HaloTag HEK293 cells in-house production with
HaloTag
113 Yes Yes
ETAR_HaloTag HEK293 cells in-house production with
HaloTag
52 Yes Yes
LMNB1_HaloTag HEK293 cells in-house production with
HaloTag
105 No –
LPLUNC1_HaloTag HEK293 cells in-house production with
HaloTag
91 Yes Yes
PECR_HaloTag NA NA – – –
PLA2R_HaloTag HEK293 cells in-house production with
HaloTag
197 Yes Yes
PRKCZ_HaloTag HEK293 cells in-house production with
HaloTag
106 No –
Transferrin_HaloTag HEK293 cells in-house production with
HaloTag
114 No –
TUBB4B_HaloTag HEK293 cells in-house production with
HaloTag
89 No –
Vimentin_HaloTag HEK293 cells in-house production with
HaloTag
96 No –
NA, not available, N-GlcNAc, N-Acetylglucosamine; see Table 1 for the full protein names and additional information.
a solution of 100 mmol/l MES (pH 6.0) containing 5 mg/ml 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride
(Pierce) and 0.2mg HaloTag Amine Ligand. After 2 h incubation
in the dark, the microspheres were washed and resuspended in
100 mmol/l MES (pH 4.5) and stored at 4◦C for at least 16 h
before using for protein coupling. Next, after aspiration the
microspheres coupled with HaloTag amine ligand were washed
with PBS-0.05% Tween-20. This suspension was incubated
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FIGURE 1 | Comparison between directly and HaloTag coupled microspheres
after incubation with commercially available animal anti-non-HLA antibodies.
For AT1R and PECR only microspheres with direct coupling were available,
therefore the comparison with HaloTag coupled microspheres cannot be
depicted. The MFI measured after incubation of the AT1R microspheres with
the anti-AT1R antibody was 13,760 and 18,842 for the PECR microspheres
after incubation with the anti-PECR antibody.
with 1ml HaloTag-protein fraction (protein concentration
ranging from 25 to 100µg/ml) for 1 h in the dark with
continuous shaking. After washing with PBS-0.05% Tween-20,
the microspheres were aspirated and blocked with PBS-0.1%
BSA-0.1% sodium azide to a final concentration of 2,500
beads/µl. The microspheres were counted on Beckman
Coulter Counter and stored in the dark at 4◦C. Coupling
efficiency was tested using anti-protein antibodies (Figure 1 and
Supplementary Table S2).
Multiplex Luminex Assay
A mix of 31 different microspheres was made consisting
of the 15 directly-coupled proteins, 13 in-house produced
HaloTag-coupled proteins, the IgG-coupled microsphere as a
positive control, the HaloTag amine-coupled microsphere, and
an empty microsphere. 1,500 microspheres per well were used
of each specificity diluted in PBS−0.1% BSA (wash buffer).
First, 48 µl diluted microsphere mix was aliquoted into a
96-well Bio-Plex Pro Flat bottom plate (Bio-Rad, Hercules,
California) and then 2µl serum was added (serum dilution 1:25).
For assay validation, instead of serum anti-protein antibodies
were added. After overnight incubation in the dark at room
temperature with continuous shaking, samples were washed
using a Bio-Plex Pro Wash station (Bio-Rad). Next, 50 µl
of 1:50 R-phycoerythrin-conjugated goat-anti human antibody
(Jackson ImmunoResearch, Cambridgeshire, UK) diluted in
wash buffer was added per well. After 30min incubation at
room temperature with continuous shaking, 50 µl wash buffer
was added and samples were measured on a Luminex 200 flow
analyzer (Luminex Corp). See Supplementary Table S3 for a list
of all antibodies used in the Luminex assay and the used dilution.
Readout is provided as median fluorescence intensity (MFI).
Commercial Autoantibody Luminex Assay
For comparison, LABScreen Autoantibody assay group 1 (Lot
1: 32 targets) and group 2 (Lot 1: 1 target) from One Lambda
(Canoga Park, CA) was used to determine the non-HLA antibody
profile in patient sera according to manufacturer’s instructions.
One Lambda donated reagents but was not involved in either the
conduct of the study or the preparation of the manuscript. In
brief, 10µl of Autoantibodymicrospheremix was incubated with
40 µl of serum in a 96 well V-bottom plate for 30min in the dark
at room temperature with continuous shaking. After washing,
PE-conjugated anti-human IgG was added and samples were
again incubated for 30min in the dark at room temperature with
continuous shaking. Finally, samples were washed again, PBS
was added and samples were measured on a Luminex 200 flow
analyzer. Readout is provided as median fluorescence intensity
(MFI) and adjusted for background by subtracting the MFI of
the negative control microsphere from the MFI of the specific
microsphere. This adjusted value is referred to as Baseline.
Serum Samples
The use of sera and experimental protocols was approved by
the Research Ethics Committee for Biobanks and the Medical
Ethics Committee of the University Medical Center Utrecht
and was performed in accordance with the FEDERA Code of
Conduct. Sera were passed through a 96-well 1.2µmMultiScreen
filter plate (Millipore, Billerica, MA) to clear debris before
used in the Luminex assay. No other serum pretreatment was
performed.
Eighteen patient sera from a national inter-laboratory
comparison of the qualitative anti-PLA2R indirect
immunofluorescence test (IIFT) were used for validation of
our PLA2R Luminex assay. The national consensus conclusions
were used to compare to MFI levels we measured. Sera of
87 controls (healthy persons fit to work or deceased donors
approved for lung donation) were used to assess non-HLA
antibodies in persons without end-stage renal disease. From
a national consortium study (2), we selected eight sera from
patients with end-stage renal disease with highMFI levels against
a variety of non-HLA specificities to test their specificity in
inhibition experiments using each produced non-HLA antigen
added in fluid phase. From the same consortium study, fourteen
sera were selected containing antibodies against 8 non-HLA
proteins both present in our assay and the commercially available
assay in order to compare results of our assay to the commercially
available Autoantibody assay.
Statistical Analysis
Statistical analyses were performed with SAS 9.4 (SAS Institute,
Cary, NC, United States). Continuous data were analyzed with
the Mann-Whitney U-test. The correlation between our assay
and the commercially available Autoantibody assay was evaluated
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using Pearson’s correlation coefficient. P<0.05 was considered as
statistically significant.
RESULTS
Protein Production
We chose two different strategies to covalently couple the
protein antigens to Luminex microspheres: (1) direct coupling
via the amino group of the protein to the carboxyl group
on the microsphere (Figure 2A) and (2) indirect (HaloTag)
coupling via the HaloTag-recombinant protein to the HaloTag
amine ligand bound to the microsphere (Figure 2B). Both
coupling strategies result in covalent and stable binding of
the proteins to the microspheres. For direct coupling we
purchased all non-HLA proteins, except PLA2R (produced in-
house), and for the coupling via the HaloTag we produced
all non-HLA proteins in-house. Table 2 provides an overview
of all proteins with their production method or source,
size including Tags, whether N-Acetylglucosamine (N-GlcNAc)
was present according to UniProt, and whether glycosylation
could be confirmed by treatment with PNGase F. We were
not able to produce AT1R and PECR in-house because
the proteins were cleaved before excretion into the culture
supernatant. Human IgG coated on microspheres was used
as a positive control, and there were four negative control
microspheres: (1) empty, (2) coated with only HaloTag amine
ligand, (3) direct-coupled transferrin, and (4) HaloTag-coupled
transferrin as autoantibodies against transferrin have not
been reported in end-stage renal disease or after kidney
transplantation.
All in-house produced proteins were generated using a
universal cloning vector including a C-terminal HaloTag and
an insert containing the sequence of the protein of interest
(see Figure 3 for the vector design). The AKTA start protein
purification system was used to remove potential (small)
contaminants such as the HaloTag protein (34 kDa) which does
not contain histidine residues. As we produced relatively low
amounts of proteins, we were not able to check for purity
by Coomassie blue protein staining. The HaloTag coupling to
the microspheres is another purification step, as HaloTag is
usually used for protein purification (as advertised by Promega).
Therefore, protein size and glycosylation status were studied
by Western blot using appropriate antibodies (Figure 4) and
compared to the predicted size (Table 2). The estimated size was
comparable to the predicted size for all 28 proteins. Glycosylation
could not be demonstrated for three of six purchased and
directly-coupled proteins with expected N-GlcNAc (APMAP,
AT1R, and ETAR), since the size of proteins was unchanged
after treatment with PNGase F (Figure 4B). The Western blot
of the purchased AT1R, purchased ETAR (both Figure 4B)
and in-house produced ETAR_HaloTag (Figure 4D) showed
multiple bands which might be caused by the presence of
SDS-PAGE and DTT stable aggregates. For the three other
proteins with N-GlcNAc used for direct coupling (Endorepellin,
LPLUNC1 and PLA2R) glycosylation could be confirmed by
PNGase F treatment. These proteins were produced in a mouse
myeloma cell line or in HEK293 cells. Also for all five HaloTag
proteins with N-GlcNAc we could confirm the glycosylation
(Figure 4D).
Validation of the Multiplex Non-HLA
Antibody Assay
After analysis of all proteins using Western blot as described
above, the proteins were coupled to MagPlex microspheres. In
order to optimize detection of non-HLA antibodies, we tested
different incubation times, incubation temperatures and serum
dilutions. Overnight incubation at room temperature using a
serum dilution of 1:25 resulted in the highest specific MFI levels
compared to minimal background signal using anti-PLA2R IIFT
positive sera (data not shown). Similar results were observed for
patient sera containing anti-Vimentin antibodies.
To assess whether the PLA2R microspheres were correctly
coupled, we used patient sera with anti-PLA2R antibodies
determined with the qualitative IIF test (Figure 5). The average
MFI ± SD for the PLA2R directly-coupled microspheres was
548 ± 390 for the PLA2R IIFT negative sera and 4,548 ±
3,256 for the PLA2R IIFT positive sera (P = 0.0008). For the
PLA2R_HaloTag microspheres this was 1,593 ± 1,408 for the
PLA2R IIFT negative sera and 7,058 ± 2,152 for the PLA2R
IIFT positive sera (P = 0.0003; Figure 5A). Even thought,
there is a high variation between the patient sera, the PLA2R
IIFT positive and negative sera could easily be distinguished
based on the measured MFI of our assay. According to the
qualitative IIF test, PLA2R positive sera could be subdivided into
weak positive and positive. Using this stratification, we plotted
the MFI values measured in our assay with the two different
PLA2R microspheres (direct and HaloTag coupling). The MFI
values of the positive sera were higher compared to the weak
positive sera (P = 0.106 for PLA2R weak positive compared
to PLA2R positive, and P = 0.048 for PLA2R_HaloTag weak
positive compared to PLA2R_HaloTag positive). In our assay we
defined that the MFI of the IgG microspheres should be at least
10,000 to assure correct secondary antibody binding, in line with
the commercially available Luminex assay to determine HLA
antibodies. The four negative control microspheres had overall
low MFI values (empty microsphere average MFI ± SD: 360
± 247; Transferrin: 692 ± 961; HaloTag amine ligand 844 ±
673; Transferrin_HaloTag 479 ± 604). 10 PLA2R IIF positive
sera were used to determine assay variation on several days
in our laboratory using the same lot. The mean coefficient of
variation was 15.1% for the MFI of PLA2R and PLA2R_HaloTag
microspheres (data not shown).
Human sera with antibodies against the other non-HLA
targets are not commercially available nor present in external
proficiency testing, as is the case for anti-PLA2R antibodies.
To test whether coupling of the microspheres was successful,
we used commercially available anti-non-HLA antibodies
(Supplementary Table S3). As the principle of ELISA is
comparable to our Luminex assay, we selected animal source
anti-non-HLA antibodies that were validated for ELISA. We
obtained validated antibodies from animal sources for 9 of the
15 non-HLA targets (Supplementary Table S3). So 6 of these
specific antibodies from animal sources were not validated
Frontiers in Immunology | www.frontiersin.org 6 December 2018 | Volume 9 | Article 3002
Kamburova et al. Multiplex Non-HLA Antibody Assay
FIGURE 2 | Schematic illustration of the direct and HaloTag coupling to the MagPlex microspheres. (A) We refer to direct coupling when the amino group of the
protein is directly coupled to the carboxylated microsphere. (B) For the HaloTag coupling a HaloTag amine ligand serves as a connection between the carboxyl group
and the HaloTag of the protein. Due to this indirect coupling, the protein of interest is freely accessible compared to the direct situation. Part of the figure is adapted
from Promega.
FIGURE 3 | Schematic illustration of a part of the universal vector used for the production of HaloTag proteins. In the general pcDNA3-WPRE vector starting with a
CMV promoter and including the HaloTag sequence and the WPRE sequence, which enhances expression, we ligated an insert consisting of a BglII restriction site,
then a signal peptide, the DNA sequence of the protein of interest, followed by 6-Histidines and ending with an XhoI restriction site.
for the use in an ELISA assay and could therefore results in
lower MFI values. Using these antibodies we compared the
MFI values for the directly- and HaloTag-coupled microspheres
(Figure 1). For most of the microspheres we observed relatively
high MFI values, confirming the coupling and recognition
of the non-HLA proteins. Potential causes of relatively low
MFI values for some microspheres could be due to the fact
that the antibody is not suitable for ELISA/Luminex, that the
epitopes these antibodies recognize are not accessible on the
direct- or HaloTag-coupled microspheres, or that the coupling
efficiency is low. To check whether the signals were specific,
we preincubated 8 patient sera, with high MFI levels against
a variety of non-HLA specificities, with the specific protein or
with transferrin (concentrations ranging from 0 to 60 ng/µl).
Inhibition in antibody binding (decrease in MFI) was observed
if sera were pre-incubated with the specific protein, whereas no
inhibition was found after preincubation with transferrin (data
not shown).
Multiplex Assay With Healthy Control Sera
Next, we screened sera of 87 healthy controls with the multiplex
non-HLA antibody assay. The control microspheres performed
as expected: IgG-MFI was above 10,000 and the 4 negative
control microspheres showed in general low MFI values (mean
MFI < 500; Figure 6A). For the direct-coupled microspheres, 8
targets had ameanMFI below 1,000 (Agrin, APMAP, ARHGDIB,
ARHGEF6, ETAR, LMNB1, LPLUNC1, and PLA2R), 4 targets
had a mean MFI between 1,000 and 1,500 (PECR, PRKCZ,
TUBB4B, and Vimentin; Figure 6B). AT1R had a mean MFI ±
SD of 3,489± 2,322. The results acquired with the direct-coupled
Endorepellin are not reliable and were excluded from further
analyses. For the direct-coupled Endorepellin, the majority of
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FIGURE 4 | Western blot of all purchased and in-house produced proteins used for direct- and HaloTag coupling to microspheres. (A) Nine purchased proteins
without an N-Acetylglucosamine (N-GlcNAc) according to UniProt (see also Table 2). Proteins were detected with either tag or protein specific antibodies as indicated.
(B) Five purchased and one in-house produced proteins (PLA2R) have an N-GlcNAc according to UniProt and were therefore treated with PNGase F to check for this
glycosylation. Proteins before and after treatment were detected with either tag or protein specific antibodies as indicated. (C) Eight in-house produced HaloTag
proteins without a GlcNAc according to UniProt were all stained with anti-HaloTag antibody. (D) Five-in-house produced HaloTag proteins with an N-GlcNAc according
to UniProt were treated with PNGase F to check for this glycosylation. These proteins were all detected before and after treatment with anti-HaloTag antibody.
microspheres had a relatively highMFI with a meanMFI± SD of
11,769 ± 7,492. This Endorepellin was produced in a mouse cell
line, and the high MFI-values appeared due to cross-reactivity
of our secondary goat anti-human antibody to mouse (data
not shown). For the HaloTag coupled microspheres, the mean
MFI values for the healthy controls were much lower compared
to the direct-coupled microspheres, except for ARHGDIB and
PLA2R (Figure 6C). Most mean MFI values for the HaloTag
coupled microspheres were below 1,000, only the mean MFI of
ARHGDIB_HaloTag was above 1,000 (mean MFI ± SD: 1,255 ±
1,532).
Comparison With Commercially Available
Autoantibody Assay
Recently, a commercial Autoantibody multiplex assay became
available which included 8 of the 14 non-HLA targets we
selected (Agrin, ARHGDIB, Endorepellin (C-terminal part LG3),
LMNB1, PECR, PLA2R, PRKCZ, and Vimentin). 14 patient sera
were selected based on a variety of MFI levels against the 8
targets in our assay. We analyzed these sera with our direct- and
HaloTag-coupled non-HLA antibody assay and compared the
baseline calculations to the commercially available autoantibody
assay. The correlation (r2) of the baseline calculations between
our assay and the commercial assay varied between 0.0903 and
0.9628 (Table 3). Although it is reassuring to see that for some
non-HLA targets there is a high correlation between our assay
and the commercial assay, it is difficult to properly compare the
assays because essential details from the commercial assay are
unknown such as protein size, glycosylation, source, purity and
coupling procedure to the microspheres.
DISCUSSION
The major objective of this study was to develop a high-
throughput non-HLA antibody assay that can be used for the
screening of kidney, heart and lung transplant recipients. At
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FIGURE 5 | Detection of anti-PLA2R antibodies in patient sera. (A) 18 patient sera [6 negative and 12 positive according to the qualitative anti-PLA2R indirect
immunofluorescence test (IIFT)] were incubated with a microsphere mix consisting of empty microspheres and microspheres coupled with HaloTag amine ligand,
Transferrin (direct-coupling), Transferrin_HaloTag (together four negative controls), coupled with IgG (positive control), and also two specific microspheres coupled with
PLA2R (direct) or PLA2R_HaloTag. The MFI values of each independent patient serum are depicted including the mean and standard deviation. (B) The 12 IIFT
positive patient sera can be divided into weak positive (n = 5) and positive (n = 7) according to the immunofluorescence staining. Using this stratification, we plotted
the MFI values measured in our assay with the two different PLA2R microspheres (direct- and HaloTag-coupling).
present, multiple commercial assays are available containing
tests to measure non-HLA antibodies against a single target.
These tests often lack details preventing in-house replication
of the manufacturing process. In this study, we transparently
provide all important details needed for the production of
reagents and development of the assay for non-HLA antibody
measurement and also mention individual failure in antigen
production. Using the information provided here, we believe
that other researchers should be able to reproduce this assay.
The selection of the fourteen non-HLA targets was hypothesis-
driven based on a literature search on the relation of non-HLA
antibodies and kidney function. The MFI values of the PLA2R
IIF positive sera were higher compared to the weak positive
sera, suggesting that our Luminex assay could be used as a
semi-quantitative diagnostics assay, which might also be helpful
for monitoring of treatment or early detection of relapse in
patients withmembranous nephropathy. Althoughwe could only
independently validate the assay with patient sera containing
anti-PLA2R determined with the qualitative IIF test, we expect
that the production and development process is optimal for the
other non-HLA targets as well, as we could confirm this using
Western blot and inhibition assays. Using this multiplex assay the
non-HLA antibody status of a patient can easily be determined
within 24 h with only 2 µl of serum needed.
In this study we coupled non-HLA antigens directly to the
microspheres as well as indirectly via a HaloTag linker. At present
it is unknown which epitopes are predominantly recognized on
each of the non-HLA antigens included, but as the coupling
process may influence the epitopes recognized, our rationale
to include both coupling procedures was to empirically find
out which coupling procedure is best suited to detect clinically
relevant non-HLA antibodies. To have all relevant epitopes
exposed upon coupling of proteins to the microspheres, we
anticipate that the HaloTag is superior to the direct-coupling,
although the trade-off is that less molecules can be bound
to individual microspheres resulting in less antibody binding
leading to lower MFI levels.
In addition, whilst time-consuming, the HaloTag system is
more flexible compared to direct coupling, allowing research
groups to produce and develop their own assay with any
protein of interest. Another major disadvantage of the direct-
coupled assay is the dependency on commercially available
proteins, (either full length proteins or peptides), and the
cell lines in which they are produced can have an effect on
posttranslational modifications such as glycosylation. For three
purchased proteins we could not demonstrate glycosylation.
This lack of glycosylation is probably explained by the in vitro
production in wheat germ (Abnova). As we don’t know the
production details of the proteins used in the commercially
available Autoantibody assay, the comparison between the assays
is probably not completely valid.
To determine whether a serum sample is positive or negative
for a non-HLA antibody, a clinically meaningful cut-off has
to be defined. The commercial autoantibody multiplex assay
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FIGURE 6 | Multiplex non-HLA antibody assay using sera of 87 healthy controls. Shown are the individual MFI values with the mean ± standard deviation (SD) for the
positive control microsphere (IgG) and the 4 negative control microspheres (A), the 13 direct-coupled microspheres (B), and the 12 HaloTag coupled microspheres (C).
TABLE 3 | Correlation between the baseline calculations of our direct- and
HaloTag-coupled multiplex assay to the commercially available Autoantibody
assay.
Coupling Protein N r2 compared to commercial assay
Direct Agrin 14 0.9628
ARHGDIB 14 0.4777
LMNB1 14 0.2635
PLA2R 14 0.5557
PRKCZ 14 0.5023
Vimentin 14 0.1133
HaloTag Agrin 14 0.0903
ARGHDIB 14 0.4984
Endorepellin (LG3) 14 0.2741
LMNB1 14 0.0243
PECR 14 0.4680
PLA2R 14 0.9371
PRKCZ 14 0.2633
Vimentin 14 0.0940
Baseline is MFI of the specific microsphere minus the MFI of negative control microsphere.
r2, Pearson Correlation.
used for comparison in this study makes use of serum samples
from non-transplanted individuals. Using the results of 100
individuals, the reference background value was calculated from
the median of the MFI plus 2 times the SD defining ∼3–5%
of healthy as being positive for non-HLA antibodies. However,
this is by definition not a clinically relevant cut-off as every
healthy individual potentially has antibodies against autoimmune
targets, and the definition used is unrelated to clinical key-
parameters such as graft loss or antibody-mediated rejection.
Patients with end-stage renal disease have massive cellular
damage in their kidneys and occurrence of cell death or apoptosis
is known to result in release of intracellular proteins which
are normally not accessible by antibodies. This release likely
results in a boost of autoantibody formation generated to clear
these antigens from the circulation, thus including a healthy
control cohort as reference for non-HLA antibody levels for
patients with end-stage renal disease may not be optimal. In
our opinion, the best way to determine the clinically relevant
cut-off for kidney transplant recipient is to use a clinical end
point such as rejection or graft failure (32). The high-throughput
multiplex non-HLA assay described here can be used to assess
defined patient groups to determine whether these 14 non-
HLA antibodies are associated with graft rejection or graft
loss. Recently, we determined the effect of pretransplant single
antigen bead-defined donor-specific HLA antibodies in 4770
kidney transplant recipients (2). This well defined cohort will be
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used to determine the clinical relevance of these pretransplant
non-HLA antibodies and results will be published in a separate
study.
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